Mixed adjuvant formulations reveal a new combination that elicits antibody response comparable to Freund’s adjuvants.

/in

Lai RP, Seaman MS, Tonks P, Wegmann F, Seilly DJ, Frost SD, LaBranche CC, Montefiori DC, Dey AK, Srivastava IK, Sattentau Q, Barnett SW, Heeney JL. Mixed adjuvant formulations reveal a new combination that elicits antibody response comparable to Freund’s adjuvants. PLoS One. 2012, 7(4): e35083.

A mouse model for HIV-1 entry.

/in

Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, Diskin R, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. A mouse model for HIV-1 entry. Proc. Natl. Acad. Sci. 2012, 109(39): 15859-64.

Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

/in

Yeh WW, Brassard LM, Miller CA, Basavapathruni A, Zhang J, Rao SS, Nabel GJ, Mascola JR, Letvin NL, Seaman MS. Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. J. Virol. 2012, 86(13): 7052-9.

Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors.

/in

Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, de Silva S, Wu L, Le Grice SFJ, Engelman A, Fuchs JR, Kvaratskhelia M. Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 2012 May 11;287(20):16801-11. doi: 10.1074/jbc.M112.354373. Epub 2012 Mar 21. PubMed PMID: 22437836; PubMed Central PMCID: PMC3351293.

Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.

/in

Liu J, Li H, Iampietro MJ, Barouch DH. Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys. J. Virol. 2012; 86:7829-7835.

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

/in

Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 2012, 18(11): 1688-92.

Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome.

/in

Handley S, Thackray LB, Zhao G, Presti R, Miller A, Droit L, Abbink P, Maxfield LF, Kambal A, Duan E, Stanley K, Kramer J, Macri SC, Permar SR, Schmitz JE, Mansfield K, Brenchley J, Veazey RS, Stappenbeck TS, Wang D, Barouch DH*, Virgin HW*. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 2012; 151:253-266.

Ad5-specific neutralizing antibodies target multiple hexon hypervariable regions.

/in

Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Ad5-specific neutralizing antibodies target multiple hexon hypervariable regions. J. Virol. 2012; 86:1267-1272.

Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys.

/in

Kaufman DR, Li F, Cruz AN, Self SG, Barouch DH. Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. Vaccine 2012; 30:506-509.

PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

/in

Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 2012, 86(8): 4394-403.